Fortress Biotech Past Earnings Performance

Past criteria checks 0/6

Fortress Biotech's earnings have been declining at an average annual rate of -13.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 17.4% per year.

Key information

-13.2%

Earnings growth rate

4.8%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate17.4%
Return on equityn/a
Net Margin-59.6%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Fortress Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:CNB0 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2483-49800
31 Mar 2485-63840
31 Dec 2385-69910
30 Sep 2362-871000
30 Jun 2363-1041080
31 Mar 2364-1001130
31 Dec 2276-951140
30 Sep 2278-971130
30 Jun 2282-931050
31 Mar 2281-74960
31 Dec 2169-65870
30 Sep 2164-38750
30 Jun 2153-33680
31 Mar 2144-43630
31 Dec 2046-47610
30 Sep 2043-576024
30 Jun 2043-545939
31 Mar 2043-545858
31 Dec 1937-405681
30 Sep 1934-455683
30 Jun 1930-515487
31 Mar 1927-535386
31 Dec 1827-735387
30 Sep 18-107-613877
30 Jun 18-65-694573
31 Mar 18-22-724869
31 Dec 1717-654952
30 Sep 17155-745749
30 Jun 17109-604741
31 Mar 1761-553936
31 Dec 1616-553335
30 Sep 164-503230
30 Jun 163-553033
31 Mar 161-492629
31 Dec 151-482230
30 Sep 151-401825
30 Jun 151-271316
31 Mar 151-251215
31 Dec 140-201010
30 Sep 140-261014
30 Jun 140-301017
31 Mar 140-361022

Quality Earnings: CNB0 is currently unprofitable.

Growing Profit Margin: CNB0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CNB0 is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.

Accelerating Growth: Unable to compare CNB0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CNB0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-22.1%).


Return on Equity

High ROE: CNB0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies